ASEAN and China Biosimilars Market by Molecule Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibody, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, and Peptide), and Application (Blood Disorder, Oncology Disease, Chronic & Autoimmune Disease, Growth Hormone Deficiency, and Others): Opportunity Analysis and Industry Forecast, 2017 - 2025
- Published Date: 2020-10-18
- Report ID: 3268
- Pages: 130
-
Format:
ASEAN and China Biosimilars Market Overview:
The ASEAN and China biosimilars market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Biosimilars or follow-on-biologics are the copied version of reference biologics, which are protected by intellectual rights that are anticipated to expire in future. The development and validation of biosimilars with reference biologics is a crucial part of the overall process. The key driving factor for biosimilars is their implied ability of providing more cost-effective treatment than branded biologics.
Key players operating in the pharmaceuticals industry are largely investing in the development of biosimilars that can be applied for the treatment of several chronic medical conditions. Biosimilars have the potential to offer up to 30% cost reduction as compared to branded biologics. This is attributed to the compact validation pathways that reduce the additional cost of clinical trials, which further assist manufacturers to achieve scale economies. The key contributing factor to the growth in demand for biosimilars across the ASEAN and Chinese market is the patent expiration of most of the blockbuster drugs in the past few years. However, the biosimilars industry is witnessing issues pertaining to achieving product efficiency while maintaining the required production capacity. This plays a pivotal role in the biosimilars industry considering the large population of ASEAN countries along with China. Progress in improving the product efficiency and quantity is expected to open new avenues for the expansion of the biosimilars market across ASEAN and China.
The ASEAN and China biosimilars market is segmented into molecule type, application, and region. Based on molecule type, the market is divided into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and peptide. Based on application, the market is classified into blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. Further, the chronic and autoimmune diseases segment is sub-categorized into diabetes, rheumatoid arthritis (RA), glaucoma, and others. Based on region, the market is analyzed across China and ASEAN region.
Key Benefits ASEAN and China Biosimilars Market:
The study provides an in-depth analysis of the ASEAN and China biosimilars market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
A qualitative analysis of the driving factors and opportunities help analyze the competitive scenario of the market.
Porters five forces analysis is provided to interpret the bargaining power of the suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.
ASEAN and China Biosimilars Key Market Segments:
By Molecule Type
Human Growth Hormone
Erythropoietin
Monoclonal Antibody
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Peptide
By Application
Blood Disorders
Oncology Diseases
Chronic and Autoimmune Diseases
Rheumatoid Arthritis (RA)
Diabetes
Glaucoma
Others
Growth Hormone Deficiency
Others
By Region
China
ASEAN Region
Singapore
Malaysia
Thailand
Indonesia
Philippines
Vietnam
Rest of ASEAN Countries
Key Market Players
3SBIO Inc.
Qilu Pharmaceutical
Novartis International AG (Sandoz International GmbH)
Pfizer Inc. (Hospira)
STADA Arzneimittel
Beijing SL Pharmaceutical Co., Ltd.
Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.)
Amgen Inc.
AstraZeneca Plc
Teva Pharmaceutical Industries Ltd.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top Winning Strategies
3.3. Porters five forces analysis
3.4. Asean biosimilars market size and forecast
3.5. China biosimilars market size and forecast
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Various blockbusters going off patent
3.6.1.2. High prevalence of chronic diseases among ageing population
3.6.1.3. Lower cost of biosimilars drugs than original biologics
3.6.2. Restraints
3.6.2.1. High initial investment in research and development
3.6.2.2. Medical efficacy and patient safety
3.6.3. Opportunity
3.6.3.1. Emergence of bio-better drugs
CHAPTER 4: ASEAN AND CHINA BIOSIMILARS MARKET, BY MOLECULE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Human growth hormone
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast
4.3. Erythropoietin
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.4. Monoclonal antibodies
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast
4.5. Insulin
4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast
4.6. Interferon
4.6.1. Key market trends and growth opportunities
4.6.2. Market size and forecast
4.7. Granulocyte-Colony Stimulating Factor
4.7.1. Key market trends and growth opportunities
4.7.2. Market size and forecast
4.8. Peptide
4.8.1. Key market trends and growth opportunities
4.8.2. Market size and forecast
CHAPTER 5: ASEAN AND CHINA BIOSIMILARS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Blood Disorders
5.2.1. Market size and forecast
5.3. Oncology Diseases
5.3.1. Market size and forecast
5.4. Chronic and Autoimmune Diseases
5.4.1. Market size and forecast
5.4.2. Rheumatoid Arthritis (RA)
5.4.2.1. Market size and forecast
5.4.3. Diabetes
5.4.3.1. Market size and forecast
5.4.4. Glaucoma
5.4.4.1. Market size and forecast
5.4.5. Others
5.4.5.1. Market size and forecast
5.5. Growth hormone deficiency
5.5.1. Market size and forecast
5.6. Others
5.6.1. Market size and forecast
CHAPTER 6: COMPANY PROFILES
6.1. 3SBIO INC.
6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance
6.1.6. Key strategic moves and developments
6.2. Qilu Pharmaceutical
6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Key strategic moves and developments
6.3. Novartis International AG (Sandoz International GmBH)
6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance
6.3.6. Key strategic moves and developments
6.4. Pfizer Inc. (Hospira)
6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance
6.4.6. Key strategic moves and developments
6.5. STADA Arzneimittel
6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Product portfolio
6.5.5. Business performance
6.6. Beijing SL Pharmaceutical Co., Ltd.
6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.7. Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.)
6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance
6.7.6. Key strategic moves and developments
6.8. Amgen Inc.
6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance
6.8.6. Key strategic moves and developments
6.9. AstraZeneca Plc
6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product Portfolio
6.9.5. Business performance
6.10. Teva Pharmaceutical Industries Ltd.
6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Product portfolio
6.10.5. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
